Q.ANT Debuts First Interactive Live Demonstration and New Benchmarks for Analog Photonic Computing at ISC 2025
Stuttgart, Germany--(Newsfile Corp. - June 4, 2025) - Q.ANT, today announced it will showcase live demonstrations of its photonic Native Processing Server (NPS) at ISC 2025, a leading global conference for high-performance computing (HPC). For the first time, attendees will be able to interact directly with functional photonic computing, witnessing how light can drive breakthroughs in energy and computational efficiency for AI, Physics Simulations, and other complex scientific workloads.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
For the first time, ISC attendees can experience analog photonic computing in action
Q.ANT's Native Processing Server (NPS) can deliver breakthrough levels of performance and energy savings
Q.ANT showcases new benchmarks in high precision and efficiency for complex AI and scientific workloads
Click image above to view full announcement.
About Q.ANT
Q.ANT is a deep-tech company pioneering photonic computing. Founded in 2018, Q.ANT develops processors that compute natively with light--delivering scalable, energy-efficient performance for next-generation AI and HPC applications. The company operates a dedicated photonic chip pilot line in Stuttgart and is currently shipping its Native Processing Server to selected partners.
Contacts:
Toni Sottak +1 843 530 4442 toni@wiredislandpr.com
Edith Laga +49 157 830 407 51 edith.laga@qant.gmbh
Source: Q.ANT GmbH
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254441
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
27 minutes ago
- Wall Street Journal
L'Oreal to Buy Majority Stake in British Skincare Brand Medik8
L'Oreal OR -0.24%decrease; red down pointing triangle said it has signed an agreement to acquire a majority stake in British skincare brand Medik8. The company said that Medik8 has strong global potential, as well as high levels of proven efficacy at an accessible price point. The acquisition will strengthen its Luxe portfolio, L'Oreal said.
Medscape
34 minutes ago
- Medscape
Lysosomal Iron Catalyzes Cell Death in Resistant Cancers
A team from French research institutes Centre national de la recherche scientifique (CNRS), Institut Curie, and Institut national de la santé et de la recherche médicale (Inserm) has discovered a new class of molecules capable of inducing the death of cancer cells that are resistant to standard treatments. The study was published in Nature on May 7. Harnessing Iron's Properties in Cancer Cells 'In certain cancers, such as pancreatic cancer or sarcomas, therapeutic options are relatively limited,' Raphaël Rodriguez, research director at CNRS and co-author of the study, told Medscape's French edition . Current cancer treatments mainly target primary tumor cells but often fail to eliminate cells with metastatic potential, which are responsible for 70% of cancer-related deaths. To address this, the team developed a new class of molecules — phospholipid degraders — designed to destroy cancer cell membranes and trigger cell death via ferroptosis. 'We used the properties of iron in cancer cells with metastatic potential. These cells express high levels of the CD44 protein on their surface, which allows them to internalize iron — a resource they need to transform and adapt to standard treatments,' Rodriguez explained. This transformation, however, also makes them more vulnerable to ferroptosis, a form of cell death catalyzed by iron. Within lysosomes — the small organelles that break down cellular debris and foreign material — iron reacts with hydrogen peroxide, generating oxygen radicals. These radicals damage lysosomal membranes and initiate a chain reaction that spreads throughout the cell, leading to the formation of peroxidized lipids in the membranes of other organelles and ultimately causing cell death. 'We were the first to link cancer, adaptability, and vulnerability to ferroptosis. Cancer cells can adapt, but they don't have a thousand identities. They have two: one that proliferates and one that spreads. Today, we target proliferation. We also need to target dissemination,' said Rodriguez. Phospholipid Degraders The researchers developed phospholipid degraders that activate ferroptosis. These molecules contain one segment that targets the cell membrane, enabling penetration and accumulation in lysosomes. A second segment enhances iron reactivity in these compartments of pro-metastatic cancer cells, triggering ferroptosis. The molecules, named fentomycin-1 (Fento-1), were made fluorescent to confirm their lysosomal localization using fluorescence microscopy. 'Ferroptosis results from the cell's inability to repair membrane damage,' Rodriguez summarized. Reduction in Tumor Growth Tested on primary patient-derived cells, tumor organoids, human biopsies, and immunocompetent animal models, these molecules demonstrated greater efficacy than standard treatments. In preclinical models of metastatic breast cancer, Fento-1 led to a significant reduction in tumor growth. It also showed strong cytotoxic effects in biopsies of pancreatic cancers and angiosarcomas. 'The most interesting results come when we combine these molecules with current treatments. The response is even better,' emphasized Rodriguez. 'We're not saying our treatment will replace existing therapies. We need a combination,' he added. The next steps include toxicity studies, followed by clinical trials. 'Industry and investors should be interested in developing this new therapeutic strategy.' This work was supported by the Ligue Contre le Cancer (Les équipes labellisées), the European Union's Horizon 2020 research and innovation programme, Fondation pour la Recherche Médicale, Fondation Charles Defforey - Institut de France, Klaus Grohe Foundation, Institut National du Cancer, Région Île-de-France, the French National Research Agency, Fondation Bettencourt Schueller, CNRS, Institut Curie, and Inserm.
Wall Street Journal
an hour ago
- Wall Street Journal
Qualcomm to Buy Alphawave IP for $2.4 Billion
U.K. semiconductor company Alphawave IP Group AWE 2.90%increase; green up pointing triangle agreed to a $2.4 billion takeover from U.S. peer Qualcomm QCOM 1.14%increase; green up pointing triangle after two months of talks. The London-listed company said Monday that accepting shareholders will get $2.48 in cash for each share held. The price equates to 183 pence a share and is a 96% premium to the company's closing price of 93.50 pence on March 31, the day before Qualcomm announced its interest.
